Abstract 465P
Background
This study evaluated the quality of oncological care of people with mental illness at an outer metropolitan centre.
Methods
A retrospective review of multidisciplinary team meetings (MDTs) was conducted and those with comorbid mental illness (“cases”) were identified. Demographic, psychiatric and oncological data were collected. Mental illness was stratified to 3 categories – Cat 1: mild affective disorders (uncomplicated depression/anxiety); Cat 2: complicated affective disorders (e.g. depression/anxiety with prior suicide attempt, hospitalisation and/or case management, substance use disorder and post-traumatic stress disorder); and Cat 3: severe mental illness (SMI) (e.g. bipolar affective disorder and schizophrenia). Patients without mental illness (“controls”) were randomly selected from the same tumour stream MDTs. Comparison between cases and controls was performed using Fisher’s exact test.
Results
Between 2021-2022, 853 patients were discussed at MDTs. 170 (20%) cases were identified, of whom 57%, 29% and 14% were in Cat 1, 2 and 3 respectively. Corresponding 170 controls were selected at random. Median age for cases was 65 vs. 71 for controls, p=0.03. No differences in sex and ethnicity were found. Cat 3 cases had the highest proportion receiving government financial aid (87%) vs. controls (57%) (Cat 1: 68%, Cat 2: 78%) p=0.001. Cat 3 cases also had the highest rates of ≥3 non-attendances to appointments (22%) vs. controls (7%) (Cat 1: 12%, Cat 2: 18%) p=0.006. Cases were found to have higher rates of metastatic disease at presentation (26% vs. 15% for controls, p=0.01). For patients offered active palliative treatment (n=80), cases had reduced adherence to the recommended treatment plan (70% vs. 91% for controls, p=0.03). Of those offered curative treatment (n=237), Cat 3 cases had the highest rates of cancer recurrence (33%) vs. controls (9%) (Cat 1: 12%, Cat 2: 18%) p=0.03.
Conclusions
Mental illness was associated with poorer cancer outcomes with increasing severity associated with even poorer outcomes, potentially reflecting higher rates of treatment non-adherence. This institutional study suggests that people with SMI have increased needs in navigating cancer care and highlights a need to examine this on a larger scale.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
Z.W. Wong: Financial Interests, Personal, Advisory Board: MSD; Financial Interests, Personal, Invited Speaker: AstraZeneca; Financial Interests, Personal, Other, Travel grant: Pfizer. Y. Antill: Financial Interests, Personal, Invited Speaker: GSK, MSD, AstraZeneca, Lilly, Eisai; Financial Interests, Institutional, Research Funding: AstraZeneca, MSD; Financial Interests, Personal, Advisory Board: GSK, MSD, AstraZeneca. All other authors have declared no conflicts of interest.
Resources from the same session
571P - Dacomitinib in treatment-naïve EGFR-mutant NSCLC patients with multiple brain metastases: Initial efficacy and safety data from a phase II study
Presenter: Yongfeng Yu
Session: Poster Display
Resources:
Abstract
572P - Multivariable five-year survival prediction model for prognosing patients with EGFR-mutated NSCLC treated with EGFR-TKIs
Presenter: Qi-An Wang
Session: Poster Display
Resources:
Abstract
573P - LUMINATE-103: Real-world treatment patterns and outcomes of patients (pts) with epidermal growth factor receptor mutant (EGFR MU), non-squamous (NSQ) locally advanced/metastatic non-small cell lung cancer (a/mNSCLC): Pooled analysis of large US electronic health record (EHR) datasets
Presenter: Byoung Chul Cho
Session: Poster Display
Resources:
Abstract
574P - Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC harboring uncommon EGFR mutations
Presenter: Lin Wu
Session: Poster Display
Resources:
Abstract
575P - Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC and brain metastasis: A multicenter cohort study
Presenter: Puyuan Xing
Session: Poster Display
Resources:
Abstract
576P - Clonality of both EGFR and co-occurring TP53 mutations affect the treatment efficacy of the third-generation EGFR-TKIs in advanced-stage EGFR-mutant non-small cell lung cancer
Presenter: Wen Feng Fang
Session: Poster Display
Resources:
Abstract
577P - A study of the efficacy and safety of amivantamab in EGFR exon 20 insertion (E20I) mutations in NSCLC
Presenter: Daeho Choi
Session: Poster Display
Resources:
Abstract
578P - Tyrosine kinase inhibitor treatment of elderly patients with epidermal growth factor receptor mutated advanced non-small cell lung cancer: A multi-institute retrospective study
Presenter: Ling-Jen Hung
Session: Poster Display
Resources:
Abstract
579P - Real-world study of dacomitinib as first-line treatment for patients with EGFR-mutant non-small cell lung cancer
Presenter: Ji Eun Shin
Session: Poster Display
Resources:
Abstract
580P - Efficacy and safety of dacomitinib as first-line treatment for advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor <italic>(EGFR)</italic> 21L858R mutation: A multicenter, ambispective, consecutive case-series study
Presenter: Shouzheng Wang
Session: Poster Display
Resources:
Abstract